Parker Waichman LLP Investigates Vision Loss Cases Linked to Ozempic and Other Semaglutide Drugs Following EMA Confirmation of NAION Risk

Port Washington, New York – October 2025 — Parker Waichman LLP, a nationally recognized plaintiffs’ law firm dedicated to representing victims of defective drugs and medical devices, is actively handling claims on behalf of individuals who have suffered vision loss after using Ozempic, Wegovy or other brand name semaglutide medications.

The European Medicines Agency (EMA) recently confirmed a potential link between semaglutide —the active ingredient in Ozempic and Wegovy—and Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION)  an irreversible eye condition that causes sudden and often permanent vision loss.

According to the EMA’s updated Summary of Product Characteristics for Ozempic:

“Data from epidemiological studies indicates an increased risk for non-arteritic anterior ischaemic optic neuropathy (NAION) during treatment with semaglutide. There is no identified time interval for when NAION may develop following treatment start. A sudden loss of vision should lead to ophthalmological examination, and treatment with semaglutide should be discontinued if NAION is confirmed.”

This finding adds to growing global concern regarding the safety of GLP-1 receptor agonist medications, including Ozempic and Wegovy, which were originally developed to treat Type 2 diabetes but are now widely prescribed for weight loss.

Legal Action and Client Representation

Parker Waichman LLP represents individuals across the United States who developed serious eye injuries—particularly vision loss or blindness related to NAION—after taking semaglutide-based drugs. The firm has already filed multiple lawsuits and continues to investigate additional claims on behalf of affected patients.

“People trusted that these medications were safe for use,” said Jason Goldstein, Senior Litigation Counsel, at Parker Waichman LLP. “This new EMA confirmation underscores what we have been seeing through our clients’ experiences—sudden, devastating loss of vision that changes lives forever.”

About NAION

Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) occurs when blood flow to the optic nerve is disrupted, leading to irreversible damage. Symptoms often include sudden vision loss in one or both eyes, usually without pain. There is currently no known cure, and vision typically does not return.

About Parker Waichman LLP

Parker Waichman LLP is one of the nation’s premier personal injury and mass tort law firms, representing clients in cases involving defective drugs, medical devices, environmental exposure, and catastrophic injury. The firm has recovered billions of dollars for clients nationwide and is recognized for its advocacy on behalf of consumers against major pharmaceutical companies.

Individuals who have experienced vision changes, partial blindness, or diagnosed NAION after taking Ozempic, Wegovy, or similar semaglutide drugs are encouraged to contact Parker Waichman LLP for a free case evaluation.

Contact:
Jason S. Goldstein, Esq.
Phone: 800-968-7529
Website: www.yourlawyer.com